TY - JOUR
T1 - Carboplatin in advanced hormone refractory prostatic cancer patients
AU - Canobbio, Luciano
AU - Guarneri, Domenico
AU - Miglietta, Loredana
AU - Decensi, Andrea
AU - Oneto, Francesco
AU - Boccardo, Francesco
PY - 1993
Y1 - 1993
N2 - 25 patients with measurable or evaluable metastatic prostate cancer, progressive after hormonal treatment, were treated weekly with carboplatin 150 mg/m2 intravenously. The weekly schedule allowed higher dose intensity carboplatin administration with respect to the common monthly cycles. Toxicity was manageable even in elderly patients with extensive bone metastases and consisted primarily of myelosuppression. 4 out of 24 evaluable patients (17%) had a partial response and 12 (50%) had disease stabilisation. The median response duration was 7 months. Prostate-specific antigen and prostatic acid phosphatase serial values showed a correlation with disease response in only 47 and 50% of patients, respectively. There results suggest that carboplatin possesses a moderate but definite activity in prostate cancer patients.
AB - 25 patients with measurable or evaluable metastatic prostate cancer, progressive after hormonal treatment, were treated weekly with carboplatin 150 mg/m2 intravenously. The weekly schedule allowed higher dose intensity carboplatin administration with respect to the common monthly cycles. Toxicity was manageable even in elderly patients with extensive bone metastases and consisted primarily of myelosuppression. 4 out of 24 evaluable patients (17%) had a partial response and 12 (50%) had disease stabilisation. The median response duration was 7 months. Prostate-specific antigen and prostatic acid phosphatase serial values showed a correlation with disease response in only 47 and 50% of patients, respectively. There results suggest that carboplatin possesses a moderate but definite activity in prostate cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0027431798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027431798&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(93)90040-M
DO - 10.1016/0959-8049(93)90040-M
M3 - Article
C2 - 7507687
AN - SCOPUS:0027431798
VL - 29
SP - 2094
EP - 2096
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 15
ER -